Lucas Bethge, Ph.D.

Vice President and Group Leader Oligonucleot at Silence Therapeutics

Speaker

Lucas Bethge studied chemistry at the Humboldt-University zu Berlin (Germany). After he obtained his Ph.D. in 2011 in Bioorganic Chemistry, he first joined NOXXON Pharma. In 2016 he moved to Silence Therapeutics GmbH, a biotech company in Berlin that develops GalNAc-conjugated siRNA for therapeutic use. Currently, he is Vice-President and leading the Oligonucleotide Chemistry group at Silence Therapeutics. Lucas is an expert for the synthesis, conjugation and analysis of oligonucleotides with over ten years of experience in industrial research and development at the interface between early research and clinical development.